Consumers in China are taking to social media to express their support for Huawei as the U.S. government looks to ramp up pressure on the Chinese smartphone maker.Technologyread more
Tensions between the two parties have heightened in recent months as the campaign for seats in the Brussels and Strasbourg-based parliament has crescendoed.Europe Politicsread more
Shares of Saudi shopping mall operator Arabian Centres were trading at 26.1 riyals ($6.96) per share just after 10 a.m. in Riyadh.IPOsread more
There is at least one thing in common between the U.S. and Russia – their willingness to weaken the European Union, a top EU official said.Politicsread more
U.S. President Donald Trump's latest tariff increase — and Beijing's plans to counter them — are hitting U.S. companies in China, according to a joint survey this month by...China Economyread more
"We are also constantly watching whether the trade war will turn into a tech war," Ma said Tuesday, according to a CNBC translation of his Chinese remarks published by a locak...China Economyread more
TransferWise, the money transfer start-up, was valued at $3.5 billion after investors bought $292 million of shares in a secondary sale.Technologyread more
Indian Prime Minister Narendra Modi's likely return to power for a second term will likely be positive for his country's growth, according to economists and investors.Asia Economyread more
Kohl's, J.C. Penney and Nordstrom release disappointing earnings news, putting a damper on their sector.Retailread more
"Pretty much the entire suite of apps that 'talk' over the internet could be vulnerable," said Tom Uren, a senior analyst at the Australian Strategic Policy Institute's...Cybersecurityread more
Bezos's comments give a rare glimpse into his interest in the auto industry. Amazon recently invested in two self-driving start-ups.Technologyread more
Emergent BioSolutions said Tuesday that the U.S. Food and Drug Administration has completed its pre-approval inspection of Emergent's large-scale facility for making BioThrax, a vaccine for pre-exposure protection against anthrax.
"Emergent is pleased to have reached this critical milestone in our BioThrax comparability program," Adam Havey, executive vice president and president of biodefense division at Emergent, said in the press release.
The company said it looks forward to "timely completing" the process of securing its FDA license for the facility, which is in Lansing, Michigan. A decision is expected by August, the company said.
BioThrax is the only approved anthrax vaccine in the U.S. The company has been supplying it to the Centers for Disease Control and Prevention as part of an effort to develop a U.S. stockpile in the event of a terrorist attack.
Anthrax is an infection caused by a spore-forming bacterium. It mainly effects animals, but humans can contract the infection through contact with infected animals or inhaling spores. Inhaled anthrax can be hard to treat and can be fatal.
Emergent's stock has dropped slightly this year, falling more than 1 percent. The company's shares were mostly unchanged, but were moving back and forth between positive and negative territory.